Serial Entrepreneur. Commercialization and distribution of medical diagnostics, treatments, imaging, biologics, as well as specialized SaaS in both medical and legal industries.
This is a very good synopsis on the mismatch between the basis for the proposed LCD policies on CAMPS and what this would yield in terms of patient and financial outcomes. Clinical efficacy data and outcomes can drive policy that will ultimately control costs if cognizant parameters are established.
Read the open letter by William Tettelbach, Martha Kelso, and David Armstrong - A review of the proposed draft CAMPs LCDs compared to evidence-based medicine: a letter to the MACs for consideration. Access it here: https://lnkd.in/eecFqF3u We encourage replies and will publish any responses we receive as commentary pieces in future issues of JWC. Please contact jwc@markallengroup.com for further details. 📩 William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP Martha R Kelso, RN, CHWS, HBOT David Armstrong